Newco Linkgevity Ltd. has won backing from the KQ Labs accelerator program at the Francis Crick Institute in London, enabling it to take forward the lead program, an anti-necrotic drug for treating ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

We recently compiled a list of the 10 Best Halal Dividend Stocks To Invest In. In this article, we are going to take a look ...

From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024 ...

Abbott Laboratories posts total worldwide sales of $10.97 billion for the quarter ended Dec. 31, missing Wall Street estimates of $11.03 billion.

AbbVie (NYSE: ABBV) could be the poster child for how to effectively navigate a patent cliff. When Abbott Labs spun off ...

But a pair of treatments that launched in 2019 are already offsetting Humira's losses. Combined sales of Skyrizi, a psoriasis ...

AbbVie closed out the year on a high note as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s final monthly ranking of the biggest TV ad spenders in biopharma.

Today, we're tracking presentations from AbbVie, UCB, WuXi AppTec and several other biopharma firms. Aside from JPM conference coverage, our reporters are making their way around town for one-on ...

In fact, the few schools that do have laboratories lack the necessary apparatus, chemical solutions, specimen samples and scientific equipment, forcing matriculation students to approach the ...

Revance's ongoing legal battle with AbbVie over Daxxify trade secrets further ... it had agreed to a merger with privately held Crown Labs, with Crown to complete a tender offer to acquire all ...